Tonix Pharmaceuticals (NASDAQ:TNXP) Director Richard Newcomb Stillwell Purchases 5,000 Shares

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Richard Newcomb Stillwell purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were purchased at an average cost of $11.65 per share, with a total value of $58,250.00. Following the completion of the purchase, the director owned 5,000 shares of the company’s stock, valued at $58,250. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Tonix Pharmaceuticals Trading Down 2.1%

Shares of Tonix Pharmaceuticals stock opened at $11.46 on Wednesday. The stock has a 50 day moving average of $13.17 and a 200 day moving average of $15.03. Tonix Pharmaceuticals Holding Corp. has a 12 month low of $10.87 and a 12 month high of $69.97. The firm has a market cap of $182.67 million, a PE ratio of -0.80 and a beta of 1.67.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Monday, May 11th. The company reported ($2.93) EPS for the quarter, missing analysts’ consensus estimates of ($2.54) by ($0.39). Tonix Pharmaceuticals had a negative net margin of 839.52% and a negative return on equity of 67.65%. The firm had revenue of $6.88 million for the quarter, compared to the consensus estimate of $6.13 million. As a group, equities research analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -9.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new stake in Tonix Pharmaceuticals during the second quarter valued at approximately $25,000. Strs Ohio raised its holdings in shares of Tonix Pharmaceuticals by 9.9% in the fourth quarter. Strs Ohio now owns 7,800 shares of the company’s stock worth $122,000 after buying an additional 700 shares during the period. Rhumbline Advisers raised its holdings in shares of Tonix Pharmaceuticals by 8.0% in the third quarter. Rhumbline Advisers now owns 12,206 shares of the company’s stock worth $295,000 after buying an additional 908 shares during the period. Bank of America Corp DE raised its holdings in shares of Tonix Pharmaceuticals by 32.7% in the third quarter. Bank of America Corp DE now owns 4,651 shares of the company’s stock worth $112,000 after buying an additional 1,146 shares during the period. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Tonix Pharmaceuticals in the third quarter worth approximately $29,000. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. TD Cowen raised Tonix Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, May 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Monday, April 20th. Finally, Wall Street Zen downgraded Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, April 26th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Tonix Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $22.00.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.